A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells

IB Barsoum, CA Smallwood, DR Siemens, CH Graham - Cancer research, 2014 - AACR
IB Barsoum, CA Smallwood, DR Siemens, CH Graham
Cancer research, 2014AACR
Immune escape is a fundamental trait of cancer in which mechanistic knowledge is
incomplete. Here, we describe a novel mechanism by which hypoxia contributes to tumoral
immune escape from cytotoxic T lymphocytes (CTL). Exposure of human or murine cancer
cells to hypoxia for 24 hours led to upregulation of the immune inhibitory molecule
programmed cell death ligand-1 (PD-L1; also known as B7-H1), in a manner dependent on
the transcription factor hypoxia-inducible factor-1α (HIF-1α). In vivo studies also …
Abstract
Immune escape is a fundamental trait of cancer in which mechanistic knowledge is incomplete. Here, we describe a novel mechanism by which hypoxia contributes to tumoral immune escape from cytotoxic T lymphocytes (CTL). Exposure of human or murine cancer cells to hypoxia for 24 hours led to upregulation of the immune inhibitory molecule programmed cell death ligand-1 (PD-L1; also known as B7-H1), in a manner dependent on the transcription factor hypoxia-inducible factor-1α (HIF-1α). In vivo studies also demonstrated cellular colocalization of HIF-1α and PD-L1 in tumors. Hypoxia-induced expression of PD-L1 in cancer cells increased their resistance to CTL-mediated lysis. Using glyceryl trinitrate (GTN), an agonist of nitric oxide (NO) signaling known to block HIF-1α accumulation in hypoxic cells, we prevented hypoxia-induced PD-L1 expression and diminished resistance to CTL-mediated lysis. Moreover, transdermal administration of GTN attenuated tumor growth in mice. We found that higher expression of PD-L1 induced in tumor cells by exposure to hypoxia led to increased apoptosis of cocultured CTLs and Jurkat leukemia T cells. This increase in apoptosis was prevented by blocking the interaction of PD-L1 with PD-1, the PD-L1 receptor on T cells, or by addition of GTN. Our findings point to a role for hypoxia/HIF-1 in driving immune escape from CTL, and they suggest a novel cancer immunotherapy to block PD-L1 expression in hypoxic-tumor cells by administering NO mimetics. Cancer Res; 74(3); 665–74. ©2013 AACR.
AACR